Pevonedistat (MLN4924) is a selective NEDD8 inhibitor. It is being investigated as a cancer treatment, e.g. for mantle cell lymphoma (MCL). NEDD8-activating...
10 KB (952 words) - 00:09, 4 January 2024
repair genes active in alternative pathways (see synthetic lethality). Pevonedistat (MLN4924), a drug inhibiting activation of NEDD8, has shown a significant...
23 KB (2,836 words) - 00:24, 8 May 2024
enzyme is critical for NEDD8 activation. Pevonedistat (MLN4924) is an analog of adenosine sulfamate. Pevonedistat is a mechanism-based inhibitor of NAE....
21 KB (2,792 words) - 22:40, 6 March 2024
investigator-initiated Phase II clinical trials of MLN4924 (also known as pevonedistat) plus Docetaxel in patients with previously treated advanced non-small...
10 KB (1,133 words) - 13:43, 23 June 2024
discoveries explained how a new experimental anti-cancer drug MLN4924 (Pevonedistat) caused over-replication of the DNA and DNA damage leading to cancer...
30 KB (2,387 words) - 22:09, 3 July 2024